|
![]() |
|
|
Terfenadine
drug data and news
Terfenadine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Terfenadine | ||
| Brand Names/Synonyms | Aldaban; Allerplus; Cyater; MDL-9918; Nebralin; RMI 9918; Seldane; Teldane; Teldanex; Terdin; Terfenadine; Terfex; Ternadin; Triludan | ||
| Indication | For the treatment of allergic rhinitis; hay fever and allergic skin disorders | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Terfenadine, an H1-receptor antagonist antihistamine, is similar in structure to astemizole and haloperidol, a butyrophenone antipsychotic. The active metabolite of terfenadine is fexofenadine. | ||
| Mechanism Of Action | Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal. | ||
| Terfenadine News (When available) |
| ||
| Dosage Forms | Oral tablets | ||
| Drug_Category | Antiarrhythmic Agents; Anti-allergic Agents; Antihistamines; ATC:R06AX12 | ||
| Absorption | On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70% | ||
| Interactions |
-->Interactions for Terfenadine: Ketoconazole Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. death, cardiac arrest, and ventricular arrhythmia including torsades de pointes. Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. Presence of unchanged terfenadine is associated with statistically significant prolongation of the QT and QTc intervals.Concomitant administration of ketoconazole and terfenadine is contraindicated. Itraconazole Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. One death has also been reported from foreign post- marketing sources. Concomitant administration of itraconazole and terfenadine is contraindicated. Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. Macrolides Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. Although erythromycin measurably decreases the clearance of the terfenadine acid metabolite, its influence on terfenadine plasma levels is still under investigation. A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin. Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. Studies to evaluate potential interactions of terfenadine with azithromycin are in progress. | ||
| Toxicity | mild (e.g., headache, nausea, confusion); but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported; LD50=mg/kg (orally in mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]-1-(4-tert-butylphenyl)-butan-1-ol | ||
| Chemical Formula | C32H41NO2 | ||
| Molecular Weight | 471.673 g/mol | ||
| Smiles String | CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O | ||
| Melting Point | 146.5-148.5°C | ||
| Water Solubility | 0.001g/100ml | ||
| State | white to off-white crystalline powder | ||
| LogP/Hphobicity | 7.784 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 3.5 hours | ||
| Protein Binding [%] | 70% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Terfenadine.html http://www.rxlist.com/cgi/generic/terfen.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00606 | ||
| CAS Registry Number | 50679-08-8 | ||
| KEGG Compound ID | C07463 | ||
| PubChem ID | SID:180732 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1913395 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |